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Introduction {#sec1}
============

Regulatory T (Treg) cells are generally regarded as one of the major obstacles to the successful clinical application of tumor immunotherapy. It has been consistently demonstrated that Treg cells contribute to the early establishment and progression of tumors in murine models and that their absence results in delay of tumor progression ([@bib8], [@bib10], [@bib13], [@bib17], [@bib26]). In humans, high tumor infiltration by Treg cells and, more importantly, a low ratio of effector T (Teff) cells to Treg cells, is associated with poor outcomes in multiple solid cancers ([@bib25]). Conversely, a high Teff/Treg cell ratio is associated with favorable responses to immunotherapy in both humans and mice ([@bib11], [@bib19]). To date, most studies support the notion that targeting Treg cells, either by depletion or functional modulation, may offer significant therapeutic benefit, particularly in combination with other immune modulatory interventions such as vaccines and checkpoint blockade ([@bib1], [@bib9], [@bib20], [@bib28]).

Defining appropriate targets for selective interference with Treg cells is therefore a critical step in the development of effective therapies. In this regard, CD25, also known as the interleukin-2 high-affinity receptor alpha chain (IL-2Rα), was the first surface marker used to identify and isolate Treg cells ([@bib22]) prior to the discovery of their master regulator, transcription factor forkhead box P3 (FoxP3). It is also the most extensively studied target for mediating Treg cell depletion. Whereas CD25 is constitutively expressed on Treg cells and absent on naive Teff cells, transient upregulation has been described upon activation of Teff cells, although these observations derive largely from in vitro studies ([@bib2]).

A number of pre-clinical studies in mice have used the anti-CD25 antibody clone PC-61 (rat IgG1, λ), which partially depletes Treg cells in the blood and peripheral lymphoid organs ([@bib24]), inhibits tumor growth, and improves survival when administered before or soon after tumor challenge ([@bib10], [@bib13], [@bib17], [@bib20], [@bib26]). However, the use of anti-CD25 as a therapeutic intervention against established tumors fails to delay tumor growth or prolong survival ([@bib10], [@bib13], [@bib17], [@bib26]). This has been attributed to several factors, including poor T cell infiltration of the tumor ([@bib20]) and potential depletion of activated effector CD8^+^ and CD4^+^ T cells that upregulate CD25 ([@bib17]). Early-phase clinical studies exploring the use of vaccines in combination with daclizumab (a humanized IgG1 anti-human CD25 antibody) ([@bib12], [@bib21]) or denileukin difitox (a recombinant fusion protein combining human IL-2 and a fragment of diptheria toxin) ([@bib7], [@bib15]) demonstrate a variable impact on the number of circulating Treg cells and vaccine-induced immunity. However, the limited indirect data assessing intra-tumoral FoxP3 transcript levels provide no clear evidence that Treg cells in the tumor microenvironment are effectively reduced and anti-tumor activity has appeared disappointing across all studies, with no demonstrable survival benefit.

The modest therapeutic activity in pre-clinical and clinical settings and concern regarding potential depletion of activated Teff cells has contributed to limited enthusiasm for the further evaluation of anti-CD25 antibodies in combination with novel immunotherapies. However, recent data demonstrate the contribution of intra-tumoral Treg cell depletion to the activity of immune modulatory antibody-based therapies and the relevance of the antibody isotype in this setting ([@bib3], [@bib5], [@bib23], [@bib27]). We therefore re-evaluated CD25 as target for Treg cell depletion and tumor immunotherapy in vivo. We demonstrated that the lack of therapeutic activity of the widely used anti-CD25 antibody (PC-61) against established mouse tumors results from a failure to effectively deplete intra-tumoral Treg cells. Optimizing FcγR binding and antibody-dependent cell-mediated cytotoxicity (ADCC) resulted in superior intra-tumoral Treg cell depletion and potent synergy when combined with programmed cell death protein-1 (PD-1) blockade. We demonstrated high levels of CD25 expression on Treg but not Teff cells in human tumors, highlighting this receptor as a clinical target and anti-CD25 as a promising therapeutic strategy in combination with novel immunotherapies.

Results {#sec2}
=======

CD25 Is Highly Expressed on Murine Tumor-Infiltrating Treg Cells {#sec2.1}
----------------------------------------------------------------

We sought to evaluate the relative expression of CD25 on individual T lymphocyte subsets within tumors (TILs) and draining lymph nodes (LNs) of mice 10 days after tumor challenge. CD25 expression appeared consistent across multiple models of transplantable tumor cell lines of variable immunogenicity including MCA205 sarcoma, MC38 colon adenocarcinoma, B16 melanoma, and CT26 colorectal carcinoma, with a higher percentage of CD25-expressing CD4^+^FoxP3^+^ Treg cells relative to CD4^+^FoxP3^−^ and CD8^+^ Teff cells ([Figure 1](#fig1){ref-type="fig"}A). In contrast to in vitro studies, minimal expression of CD25 on the Teff cell compartment was observed in vivo and the percentage of CD25-expressing Teff cells (CD8^+^ = 3.08%--8.35%, CD4^+^FoxP3^−^ = 14.11%--26.87%) was significantly lower than on Treg cells (83.66%--90.23%) (p \< 0.001) ([Figure 1](#fig1){ref-type="fig"}B). CD25 expression was also observed on Treg cells present in LNs and blood (data not shown). However, the level of expression, based on mean fluorescence intensity (MFI), was significantly lower than that observed on tumor-infiltrating Treg cells ([Figure 1](#fig1){ref-type="fig"}C). Based on these data, CD25 appeared an attractive target for preferential depletion of Treg cells.Figure 1Anti-CD25-r1-Mediated Depletion of CD25^+^ Regulatory T Cells Is Restricted to Blood and Lymph Nodes(A--C) Mouse LNs and TILs were analyzed by flow cytomery 10 days after MCA205 (n = 10), MC38 (n = 5), B16 (n = 3), or CT26 (n = 3) tumor implantation.(A) CD25 expression on T cell subsets in representative mice. Dotted lines indicate the gate.(B and C) Percentage (B) and MFI (C) of CD25 in each T cell subset. Error bars show standard error of the mean (SEM). p values obtained by two-way analysis of variance (ANOVA).(D--G) Tumor-bearing mice were injected with 200 μg of αCD25-r1, αCD25-m2a, or αCTLA-4 on days 5 and 7 after MCA205 tumor implantation. Blood, LNs, and TILs were harvested and processed on day 9 for flow cytometry analysis.(D) Representative plots showing expression of CD25 (detected with antibody clone 7D4) and FoxP3 in CD3^+^CD4^+^ T cells. Numbers show percentage of cells in each quadrant.(E) MFI of CD25 in CD4^+^FoxP3^+^ Treg cells.(F) Percentage of FoxP3^+^ Treg cells of total CD3^+^CD4^+^ T cells.(G) CD8^+^/Treg cell ratios (n = 10). Experiment was repeated three times.

Anti-CD25-Mediated Depletion of Treg Cells Is Limited to Lymph Nodes and Blood {#sec2.2}
------------------------------------------------------------------------------

Based on evidence demonstrating the contribution of intra-tumoral Treg cell depletion to the activity of immune modulatory antibodies ([@bib3], [@bib5], [@bib23], [@bib27]), we sought to compare the impact of anti-CD25 (clone PC-61 rat IgG1, αCD25-r1) on the frequency of Teff and Treg cells in the blood, LNs, and TILs of mice with established tumors. We focused our analyses on the MCA205 model because of its higher immunogenicity in order to determine any potential negative impact of αCD25 on activated Teff cells within tumors.

As previously described ([@bib17], [@bib24]), administration of 200 μg of αCD25-r1 on days 5 and 7 after tumor challenge resulted in a reduced frequency of CD25^+^ cells in all analyzed sites ([Figures 1](#fig1){ref-type="fig"}D and 1E) and a reduction in the frequency of CD4^+^FoxP3^+^ Treg cells in blood and LN ([Figure 1](#fig1){ref-type="fig"}F). However, αCD25-r1 failed to deplete tumor-infiltrating Treg cells, which demonstrated a CD4^+^FoxP3^+^ CD25^−^ phenotype after therapy. Their frequency remained comparable to that of untreated mice ([Figure 1](#fig1){ref-type="fig"}F), potentially explaining the lack of efficacy observed against established tumors in previous studies despite an apparent reduction in CD25^+^ T cells within the tumor ([@bib10], [@bib13], [@bib17], [@bib20], [@bib26]).

We next investigated whether an antibody with optimized ADCC activity could efficiently deplete intra-tumoral Treg cells without significant impact on Teff cells. We replaced the constant regions of the original αCD25 obtained from clone PC-61 with murine IgG2a and κ constant regions (αCD25-m2a), the classical mouse isotype associated with ADCC, and compared its activity to that of αCD25-r1 in vivo. While both antibody variants resulted in reduced expression of CD25 on T cells and a reduction in the number of Treg cells in blood and LNs, only αCD25-m2a resulted in depletion of tumor-infiltrating Treg cells to levels comparable to those observed with anti-cytotoxic T lymphocyte associated protein-4 (αCTLA-4, clone 9H10), which is known to preferentially deplete Treg cells in the tumor but not the periphery ([Figures 1](#fig1){ref-type="fig"}D--1F; [@bib23], [@bib27]). In keeping with these observations, both αCD25 isotypes resulted in an increased Teff/Treg cell ratio in circulating lymphocytes and LN, but only αCD25-m2a increased the intra-tumoral ratio in a similar manner to αCTLA-4 ([Figure 1](#fig1){ref-type="fig"}G). Despite a reduction in the number of circulating and LN-resident Treg cells, no macroscopic, microscopic, or biochemical evidence of toxicity was observed in the skin, lungs, or liver after multiple doses of αCD25-m2a ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C).

High Expression of FcγRIIb Inhibits αCD25-r1-Mediated Treg Cell Depletion in the Tumor {#sec2.3}
--------------------------------------------------------------------------------------

Anti-CD25-r1 has been described to deplete circulating Treg cells by FcγRIII-mediated ADCC ([@bib24]). However, its intra-tumoral activity has not been investigated. To determine this, we characterized the expression of Fc-gamma receptors (FcγRs) on different leukocyte subpopulations in the blood, spleen, LN, and tumor of mice bearing MCA205 tumors ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}). The percentage of FcγR-expressing cells appeared higher on tumor-infiltrating myeloid cells (granulocytic cells, dendritic cells, and monocyte/macrophages) relative to all other studied organs ([Figures 2](#fig2){ref-type="fig"}A and 2B). We then analyzed the binding affinity of the two Fc variants of αCD25 to FcγRs ([Figure 2](#fig2){ref-type="fig"}C). As previously described ([@bib16]), the mIgG2a isotype binds to all FcγR subtypes with a high activatory to inhibitory ratio (A/I). In contrast, the rIgG1 isotype binds with a similar affinity to a single activatory FcγR, FcγRIII, as well as the inhibitory FcγRIIb, resulting in a low A/I ratio (\<1) ([Figure 2](#fig2){ref-type="fig"}C).Figure 2FcγRIIb Inhibits αCD25-r1-Mediated Treg Cell Depletion in Tumors(A and B) Expression of FcγRs was measured by flow cytometry in leukocytes from blood, spleen, LNs, and MCA205 tumors (TIL) 10 days after tumor implantation.(A) Expression of FcγRs on granulocytes (CD11b^+^Ly6G^+^), conventional dendritic cells (cDCs) (CD11c^hi^MHC-II^+^), and monocyte/macrophages (Mono/Mφ) (CD11b^+^Ly6G^−^NK1.1^−^CD11c^lo/neg^). Dotted lines indicate the gate, numbers show the percentage of positive cells.(B) Cumulative data of FcγR expression in cell subpopulations (n = 3). Error bars represent SEM; the experiment was repeated three times.(C) Binding affinity of rat IgG1 and mouse IgG2a isotypes to individual mouse FcγRs as determined by surface plasmon resonance (SPR).(D--G) Percentage of CD4^+^FoxP3^+^ Treg cells of total CD4^+^ T cells in TILs of wild-type (WT, n = 5--10), *Fcer1g*^*−/−*^ (n = 10), *Fcgr3*^*−/−*^ (n = 5), *Fcgr4*^*−/−*^ (n = 10), or *Fcgr2b*^*−/−*^ (n = 5) mice treated as in [Figures 1](#fig1){ref-type="fig"}D--1G.

To determine which specific FcγRs were involved in αCD25-mediated Treg cell depletion, we quantified the number of tumor-infiltrating Treg cells in mice lacking expression of different FcγRs ([Figures 2](#fig2){ref-type="fig"}D--2G). Analysis of *Fcer1g*^−/−^ mice, which lack expression of activating FcγRs (I, III, and IV), demonstrated a complete absence of Treg cell depletion. Treg cell elimination by αCD25-r1 in the periphery and by αCD25-m2a in the periphery and tumor therefore results from FcγR-mediated ADCC and not blocking of IL-2 binding to CD25 ([Figure 2](#fig2){ref-type="fig"}D). Depletion by αCD25-m2a was not dependent on any individual activatory FcγR, with Treg cell elimination maintained in both *Fcgr3*^*−/−*^ and *Fcgr4*^*−/−*^ mice ([Figures 2](#fig2){ref-type="fig"}E and 2F). In keeping with previous studies ([@bib24]), we confirmed that depletion of peripheral Treg cells by αCD25-r1 depends on FcγRIII (data not shown), but it fails to deplete in the tumor despite high intra-tumoral expression of this receptor ([Figure 2](#fig2){ref-type="fig"}E). Intra-tumoral Treg cell depletion was, however, effectively restored in mice lacking expression of the inhibitory receptor FcγRIIb. In this setting, intra-tumoral Treg cell depletion was comparable between αCD25-r1 and αCD25-m2a ([Figure 2](#fig2){ref-type="fig"}G). Therefore, the lack of Treg cell depletion by αCD25-r1 in the tumor is explained by its low A/I binding ratio and high intra-tumoral expression of FcγRIIb. FcγRIIb has been associated with modulation of ADCC in tumors ([@bib4]), and in this case inhibits ADCC mediated by the single activatory receptor engaged by the αCD25-r1 isotype.

Anti-CD25-m2a Synergizes with Anti-PD-1 to Eradicate Established Tumors {#sec2.4}
-----------------------------------------------------------------------

To determine whether the enhanced intra-tumoral Treg cell-depleting activity of αCD25-m2a could improve therapeutic outcomes, we compared the anti-tumor activity of αCD25-m2a and -r1 against established tumors. We administered a single dose of αCD25 5 days after subcutaneous implantation of MCA205 cells, when tumors were established with an average diameter of 4--5 mm. Consistent with the observed lack of capacity to deplete intra-tumoral Treg cells ([Figure 1](#fig1){ref-type="fig"}F) and previous studies ([@bib10], [@bib13], [@bib17], [@bib20], [@bib26]), αCD25-r1 failed to control tumor growth. Conversely, growth delay and long-term survival was observed in a proportion of mice receiving αCD25-m2a (15.4%) ([Figures 3](#fig3){ref-type="fig"}A and 3B).Figure 3Synergistic Effect of Anti-CD25-m2a and Anti-PD-1 Combination Results in Eradication of Established TumorsTumor-bearing mice were treated with 200 μg of αCD25 on day 5 and 100 μg of αPD-1 on days 6, 9, and 12 after tumor implantation.(A) Growth curves of individual MCA205 tumors, showing the product of three orthogonal tumor diameters. The number of tumor-free survivors is shown in each graph.(B) Survival of mice shown in (A).(C and D) Survival of mice with MC38 or CT26 tumors treated as described above (n = 10 per condition).(E) Percentage of Ki67^+^ cells in tumor-infiltrating CD4^+^FoxP3^−^ and CD8^+^ T cells.(F) CD4^+^FoxP3^−^/CD4^+^FoxP3^+^ and CD8^+^/CD4^+^FoxP3^+^ cell ratios.(G and H) Representative histograms (G) and percentage (H) of IFN-γ-producing CD4^+^ and CD8^+^ TILs in MCA205 tumors determined by intracellular staining after ex vivo re-stimulation with PMA and ionomycin. Graphs show cumulative data of two separate experiments (n = 10).

Based on its role in T cell regulation within the tumor microenvironment and the observed clinical activity of agents targeting the PD-1-PD-L1 axis, we hypothesized that depletion of CD25^+^ Treg cells and PD-1 blockade might be synergistic in combination. In the same model, blocking anti-PD-1 antibody (αPD-1, clone RMP1-14) at a dose of 100 μg every 3 days was ineffective in the treatment of established MCA205 tumors when used as monotherapy or in combination with αCD25-r1 ([Figures 3](#fig3){ref-type="fig"}A and 3B). However, a single dose of αCD25-m2a followed by αPD-1 therapy eradicated established tumors in 78.6% of the mice, resulting in long-term survival of more than 100 days ([Figures 3](#fig3){ref-type="fig"}A and 3B). This activity was significantly reduced in the absence of CD8^+^ T cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), demonstrating that tumor elimination depends on the impact of the αPD-1 and αCD25 combination on both CD8^+^ and Treg cell compartments, and that overall effector T cell responses are not negatively impacted by a depleting αCD25 antibody.

Similar findings were observed in MC38 and CT26 tumor models, where αCD25-m2a had a partial therapeutic effect that synergized with αPD-1 therapy ([Figures 3](#fig3){ref-type="fig"}C and 3D). Activity was also observed against the poorly immunogenic B16 melanoma tumor model when αCD25-m2a and αPD-1 were combined with a granulocyte-macrophage colony stimulating factor (GM-CSF)-expressing whole tumor cell vaccine (Gvax). As previously described, in this system, Gvax alone failed to extend survival of tumor-bearing mice ([@bib19], [@bib30]). Combination therapy with αCD25-m2a and αPD-1 translated into a modest increase in survival, which was not observed with αCD25-r1 and αPD-1 ([Figure S4](#mmc1){ref-type="supplementary-material"}).

To understand the mechanisms underpinning the observed synergy, we evaluated the phenotype and function of TILs in MCA205 tumors at the end of the treatment protocol, 24 hr after the third dose of αPD-1 ([Figures 3](#fig3){ref-type="fig"}E--3H). Monotherapy with αPD-1 did not impact upon Teff cell proliferation ([Figure 3](#fig3){ref-type="fig"}E) nor the number infiltrating the tumor, where a persisting high frequency of Treg cells was observed (data not shown), resulting in a low Teff/Treg ratio ([Figure 3](#fig3){ref-type="fig"}F) and lack of therapeutic activity. Conversely, intra-tumoral Treg cell depletion with αCD25-m2a resulted in a higher proportion of proliferating and interferon-γ (IFN-γ)-producing CD4^+^ and CD8^+^ T cells in the tumor, corresponding to a high Teff/Treg cell ratio and anti-tumor activity ([Figures 3](#fig3){ref-type="fig"}E--3H). This effect was further enhanced in combination with αPD-1, which yielded even higher proliferation and a 1.6-fold increase in the number of IFN-γ-producing CD4^+^ and CD8^+^ T cells compared to αCD25-m2a alone. In contrast, the observed lack of Treg cell depletion with αCD25-r1 resulted in no change in Teff cell proliferation or IFN-γ production, when used as monotherapy or in combination with αPD-1 ([Figures 3](#fig3){ref-type="fig"}E--3H). Combination of αCD25 and αPD-1 therefore appeared highly effective at rejecting established tumors, but only when intra-tumoral Treg cells were efficiently depleted by αCD25 of appropriate isotype.

CD25 Expression Profiles in Human Cancers Validate Its Use as Target for Therapeutic Treg Cell Depletion {#sec2.5}
--------------------------------------------------------------------------------------------------------

To validate the translational value of CD25 as a target for Treg cell depletion, we analyzed the expression of CD25 on peripheral blood mononuclear cells (PBMCs) and TILs in patients with advanced melanoma, early-stage non-small cell lung carcinoma (NSCLC), and renal cell carcinoma (RCC) by flow cytometry and multiplex immunohistochemistry (IHC). Despite heterogeneity in clinical characteristics both within and between studied cohorts ([Tables S1--S3](#mmc1){ref-type="supplementary-material"}), CD25 expression remained largely restricted to CD4^+^FoxP3^+^ Treg cells (mean % CD25^+^ = 54.8% of Treg, 7.5% of CD4^+^FoxP3^−^, and 1.9% of CD8^+^; p \< 0.0001) ([Figures 4](#fig4){ref-type="fig"}A and 4B). Similar to murine models, the level of CD25 expression, as assessed by MFI, was significantly higher on CD4^+^FoxP3^+^ Treg cells relative to CD4^+^FoxP3^−^ and CD8^+^ T cells within all studied tumor subtypes (mean MFI Treg = 190.0, CD4^+^FoxP3^+^ = 34.5 and CD8^+^ = 17.9; p \< 0.0001) ([Figure 4](#fig4){ref-type="fig"}C).Figure 4CD25 Is Highly Expressed on Treg Cell Infiltrating Human Tumors(A) Representative histograms demonstrating CD25 expression on circulating (PBMC) and tumor-infiltrating (TIL) CD8^+^, CD4^+^FoxP3^−^, and CD4^+^FoxP3^+^ T cell subsets. Dotted lines indicate the gate.(B and C) Quantification of CD25 expression (percentage \[B\] and MFI \[C\]) on individual T cell subsets in human melanoma (n = 11), NSCLC (n = 9), and RCC (n = 8). Error bars represent SEM; p values obtained by two-way ANOVA.(D) Longitudinal analysis of CD25 expression in human melanoma and RCC lesions prior to ("Baseline") and during PD-1 blockade ("On therapy"). CD8 staining is displayed in red, FoxP3 in blue, and CD25 in brown.(E) Percentage of CD25 expression on CD8^+^ and FoxP3^+^ T cells at baseline and during PD-1 blockade. Plotted values derive from analysis of 10 ×40 high-power fields per patient at each time point.

We further performed longitudinal assessment of CD25 expression in the context of immune modulation. Core biopsies were performed on the same lesion at baseline and after either four cycles of nivolumab (3 mg/kg Q2W) or two cycles of pembrolizumab (200 mg Q3W) in patients with advanced kidney cancer and melanoma, respectively ([Table S4](#mmc1){ref-type="supplementary-material"}). Despite systemic immune modulation, CD25 expression remained restricted to FoxP3^+^ Treg cells, even in areas of dense CD8^+^ T cell infiltrate evaluated by multiplex immunohistochemistry ([Figures 4](#fig4){ref-type="fig"}D and 4E). These findings confirmed the translational value of the described pre-clinical data, lending further support to the concept of selective therapeutic targeting of Treg cells via CD25 in human cancers.

Discussion {#sec3}
==========

We have demonstrated that CD25 is an attractive target for Treg cell depletion owing to its expression profile on tumor-infiltrating T cells in both mice and humans. Contrary to in vitro studies, minimal expression of CD25 on the effector compartment was observed in vivo. The efficacy of αCD25 as an anti-tumor therapy depends on Treg cell depletion in the tumor microenvironment, which can be achieved only by using an antibody isotype optimized for engagement of activating FcγRs, capable of inducing ADCC. Our results demonstrated that the limited efficacy observed in pre-clinical studies using the αCD25 PC-61 monoclonal antibody with a rat IgG1 isotype relates to ineffective or suboptimal intra-tumoral Treg cell depletion, a consequence of its low A/I binding ratio and high intra-tumoral expression of inhibitory FcγRIIb. This may also explain the modest results observed in early clinical trials using the anti-human CD25 antibody daclizumab. However, the impact of αCD25 antibodies of varying IgG subclass remains to be evaluated in humans.

Local depletion of tumor-infiltrating Treg cells by αCD25 monotherapy mediated only partial tumor control, suggesting that further intervention is necessary to increase the intra-tumoral Teff/Treg cell balance and promote effector T cell activity. These data mirror those previously demonstrated for αCTLA-4 antibodies, where targeting solely the Treg cell compartment was ineffective in eradicating established tumors, while targeting both Treg and Teff cell compartments resulted in effective therapeutic synergy ([@bib18]). Increased regulation of Teff cell responses by co-inhibitory immune checkpoints in the tumor microenvironment might also explain the modest responses observed in early-stage clinical trials evaluating αCD25 antibodies in cancer patients ([@bib12], [@bib21]). Our data suggest that such responses could be enhanced through combination with therapies that address this regulation including immune checkpoint blockade or agonistic antibodies targeting immune co-stimulatory receptors.

Treg cell depletion can be achieved by targeting other molecules highly expressed on Treg cells ([@bib3], [@bib5], [@bib23], [@bib27]). While combined blocking and depleting activity of specific immune modulatory antibodies is effective against certain target molecules, such as CTLA-4, it can also be deleterious owing to simultaneous high expression on Teff cells. Differential expression is therefore critical; for example, in addition to its expression on Treg cells, PD-1 is highly expressed on activated CD8^+^ T cells. Anti-PD-1 antibodies therefore lose anti-tumor activity when a depleting antibody isotype is employed ([@bib6]).

Anti-PD-1 therapy now forms a key part of the treatment paradigm for multiple solid malignancies, with response rates varying between 20% and 30% when used as monotherapy ([@bib29]). However, the majority of responses are partial. This could be explained in part by tumor infiltration with CD25^+^FoxP3^+^ Treg cells that are unaffected by non-depleting αPD-1 antibodies. In this setting another target molecule specific to Treg cells is required in order to achieve potential synergy through Treg cell depletion. Combination of αCTLA-4 and αPD-1 therapy has achieved superior response rates to either agent alone in patients with advanced melanoma ([@bib14]). This may be the result of the cell-intrinsic immune modulatory activity of αCTLA-4 and αPD-1 antibodies and concomitant depletion of Treg cells by αCTLA-4, although this second activity has not been demonstrated in vivo. Combination therapy results in higher immune-related toxicity, underscoring the need for alternative combinations balancing maximal activity with minimal toxicity. We have demonstrated that αCD25 therapy synergizes with blocking αPD-1 therapy, provided Treg cells are depleted locally in the tumor. Combining αPD-1 with αCD25-depleting antibodies might improve the therapeutic window compared to the αCTLA-4 combination, as αCD25 lacks the additional cell-intrinsic immune modulatory activity of αCTLA-4. Such hypotheses are further supported by our model, in which only transient Treg cell depletion was required for effective synergy, with no evidence of immune-related toxicity. These data support further evaluation of Fc-optimized αCD25 as a combination partner in clinical trials.

Experimental Procedures {#sec4}
=======================

Antibodies and Antibody Production {#sec4.1}
----------------------------------

The sequence of the variable regions of the heavy and light chains of αCD25 were resolved from the PC-61.5.3 hybridoma by rapid amplification of cDNA ends (RACE), cloned into the constant regions of murine IgG2a and κ chains and expressed in a stable K562 cell line generated by co-transduction with murine leukemia virus-derived retroviral vectors encoding both chains. The antibody was initially purified from supernatants with a protein G HiTrap MabSelect column (GE Healthcare), dialyzed in phosphate-buffered saline (PBS), concentrated, and filter-sterilized. For subsequent experiments, antibody production was outsourced to Evitria AG. Anti-CD25-r1 (PC-61.5.3), αCTLA-4 (9H10), αPD-1 (RMP1-14), and αCD8 (2.43) were supplied by BioXcell. The binding affinity of isotype variants to FcγRs was measured by SPR in the Ravetch laboratory as described before ([@bib16]).

Tumor Experiments {#sec4.2}
-----------------

Details of mouse strains, cell lines and flow cytometry antibodies are shown in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Mice were injected subcutaneously with 5 × 10^5^ MCA205, MC38, or CT26 cells or 5 × 10^4^ B16 cells re-suspended in PBS. Therapeutic antibodies were administered intraperitoneally at the time points and doses shown in figure legends. Cell suspensions for flow cytometry were prepared as described previously ([@bib27]). Tumors were measured twice weekly and mice were euthanized when any orthogonal tumor diameter reached 150 mm.

Human Study Oversight {#sec4.3}
---------------------

Human data derives from three translational studies approved by local institutional review board and Research Ethics Committee (Melanoma, REC no. 11/LO/0003; NSCLC, REC no.13/LO/1546; RCC, REC no. 11/LO/1996). All were conducted in accordance with the provisions of the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients (or their legal representatives) provided written informed consent before enrollment.

Analysis of Human Tissue {#sec4.4}
------------------------

For flow cytometry, cell suspensions were prepared with the same protocol employed for mouse tissues ([@bib27]). Leukocytes were enriched by gradient centrifugation with Ficoll-paque (GE Healthcare). Isolated live cells were frozen at −80°C and stored in liquid nitrogen until analysis.

Histopathology protocols are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Data Analysis {#sec4.5}
-------------

Flow cytometry data were analyzed with FlowJo v10.0.8 (Tree Star). Statistical analyses were done with Prism 6 (GraphPad Software); p values were calculated using Kruskall-Wallis and Dunn's post hoc tests, unless otherwise indicated (ns = p \> 0.05; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; ^∗∗∗∗^p ≤ 0.0001). Kaplan-Meier curves were analyzed with the log-rank test.
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